Conference Coverage

International expert group agrees on redefining psoriasis severity

Publish date: December 1, 2020

 

FROM MEDSCAPELIVE LAS VEGAS DERMATOLOGY SEMINAR

MedscapeLive and this news organization are owned by the same parent company.

bjancin@mdedge.com

Pages

Recommended Reading

Non-Whites remain sorely underrepresented in phase 3 psoriasis trials
MDedge Rheumatology
Data on potential risks of COVID-19 in psoriasis patients limited, but reassuring
MDedge Rheumatology
Mirikizumab beats placebo, secukinumab for psoriasis
MDedge Rheumatology
Topical tapinarof effective in pivotal psoriasis trials
MDedge Rheumatology
Methotrexate users need tuberculosis tests in high-TB areas
MDedge Rheumatology
Chronic inflammatory diseases vary widely in CHD risk 
MDedge Rheumatology
Tildrakizumab for psoriasis shows durable efficacy over 5 years
MDedge Rheumatology
TNF inhibitor–induced psoriasis treatment algorithm maintains TNF inhibitor if possible
MDedge Rheumatology
Expanded indications likely for apremilast
MDedge Rheumatology
The case for anti–IL-17 agents as first-line biologics in psoriatic arthritis
MDedge Rheumatology